Nox isoforms in vascular pathophysiology: insights from transgenic and knockout mouse models
Source: Redox Report, Volume 15, Number 2, April 2010 , pp. 50-63(14)
Publisher: Maney Publishing
Abstract:Elevated reactive oxygen species (ROS) formation in the vascular wall is a key feature of cardiovascular diseases and a likely contributor to oxidative stress, endothelial dysfunction and vascular inflammation. The NADPH oxidases are a family of ROS generating enzymes, of which four members (Nox1, Nox2, Nox4 and Nox5) are expressed in blood vessels. Numerous studies have demonstrated that expression and activity of at least two isoforms of NADPH oxidase – Nox1 and Nox2 – are up-regulated in animal models of hypertension, diabetes and atherosclerosis. However, these observations are merely suggestive of a role for NADPH oxidases in vessel pathology and by no means establish cause and effect. Furthermore, questions surrounding the specificity of current pharmacological inhibitors of NADPH oxidase mean that findings obtained with these compounds must be viewed with caution. Here, we review the literature on studies utilising genetically-modified mouse strains to investigate the roles of NADPH oxidases in experimental models of vascular disease. While several studies on transgenic over-expressing or knockout mice support roles for Nox1- and/or Nox2-containing oxidases as sources of excessive vascular ROS production and causes of endothelial dysfunction in hypertension, atherosclerosis and diabetes, there are still no published reports on the effects of genetic modification of Nox4 or Nox5 in vascular or indeed any other contexts. Further understanding of the roles of specific isoforms of NADPH oxidase in vascular (patho)physiology should provide direction for future programs aimed at developing selective inhibitors of these enzymes as novel therapeutics in cardiovascular disease.
Document Type: Review Article
Affiliations: 1: Department of Pharmacology, Monash University, Clayton, Victoria, Australia; Department of Microbiology and Immunology, University of Melbourne, Parkville, Victoria, Australia 2: Department of Pharmacology, Monash University, Clayton, Victoria, Australia 3: Department of Microbiology and Immunology, University of Melbourne, Parkville, Victoria, Australia 4: Department of Pharmacology, Monash University, Clayton, Victoria 3800, Australia. Grant.Drummond@med.monash.edu.au
Publication date: 2010-04-01